ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.939,99
0,10%
S&P 500
5.018,39
-0,34%
Dow Jones
37.903,29
0,00%
Euro vs US Dollar
1,07015
-0,15%
Bitcoin
59.072,37
1,43%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. Charles River Laboratories International Inc (CRL)

  7. Charles River Laboratories International Inc (CRL) News

CRL Charles River Laboratories International Inc

232,69
0,00 (0,00%)
Vor Marktöffnung
Zuletzt aktualisiert: 13:00:00
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Charles River Laboratories International Inc CRL NYSE Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,00 0,00% 232,69 13:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
232,69
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
02.5.202414:00BWCharles River Launches Viral Vector Reference Materials to..
22.4.202414:00BWCharles River Laboratories Achieves 100% Renewable..
16.4.202414:00BWCharles River Laboratories Launches Alternative Methods..
12.4.202414:00BWCharles River Laboratories Schedules First-Quarter 2024..
11.4.202414:00BWCharles River and Deciphex Launch Patholytix Foresight, a..
09.4.202414:00BWCharles River Announces Rare Disease Gene Therapy..
04.4.202414:00BWCharles River to Perform Plasmid Production for Ship of..
01.4.202414:00BWCharles River Laboratories Showcases Technology-Driven..
27.3.202413:00BWCharles River Laboratories Publishes 2023 Corporate..
21.3.202413:00BWCharles River Announces Extension of Gene Therapy..
14.3.202413:00BWCharles River and Navega Therapeutics Announce Comprehensive..
12.3.202413:00BWCharles River Laboratories to Present at Barclays Global..
11.3.202421:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.3.202420:34EDGAR2Form 144 - Report of proposed sale of securities
05.3.202422:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.3.202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.3.202418:47EDGAR2Form 144 - Report of proposed sale of securities
01.3.202423:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202421:14EDGAR2Form 144 - Report of proposed sale of securities
29.2.202418:42EDGAR2Form 144 - Report of proposed sale of securities
29.2.202408:00PRNUSWheeler Bio Seals Agreement with Charles River to Offer..
23.2.202422:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202417:09EDGAR2Form 144 - Report of proposed sale of securities
21.2.202414:00BWCharles River and Wheeler Bio Complete Agreement to..
20.2.202423:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.2.202423:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.2.202423:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.2.202414:08BWCharles River Collaborates with Pluristyx, Expanding its..
17.2.202400:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202422:04EDGAR2Form 144 - Report of proposed sale of securities
15.2.202417:02EDGAR2Form 144 - Report of proposed sale of securities
14.2.202413:30EDGAR2Form 8-K - Current report
14.2.202413:00BWCharles River Laboratories Announces Fourth Quarter and..
06.2.202402:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.2.202401:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.2.202401:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202423:34EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
31.1.202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202423:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202423:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202423:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202423:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202422:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.1.202414:00BWCharles River Introduces the First Rapid Animal-Free..
24.1.202422:34EDGAR2Form 8-K - Current report
24.1.202422:30BWCharles River Laboratories Adds Reshema Kemps-Polanco to..
23.1.202422:30BWCharles River Laboratories Schedules Fourth-Quarter 2023..
16.1.202422:32EDGAR2Form 8-K - Current report
16.1.202414:00BWCharles River Launches Rep/Cap Plasmids to Streamline..
11.1.202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Kürzlich von Ihnen besucht

NYSE
CRL
Charles River Laboratories
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten